Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
MK-677: Contraindications & Drug Interactions
Safety information for MK-677 including known contraindications, drug interactions, and important precautions.
Back to MK-677 overviewContraindications
- Diabetes or impaired glucose tolerance (raises blood glucose)
- Active malignancy
- Congestive heart failure (fluid retention risk)
- Pregnancy and breastfeeding
Drug Interactions (5 interactions)
Important: This table summarizes known and theoretical interactions. Always consult a healthcare provider before combining MK-677 with any medication.
| Drug | Classification | Mechanism |
|---|---|---|
| Insulin / oral hypoglycemics | Documented | MK-677 increases fasting glucose and insulin resistance — dose adjustments needed |
| Somatostatin analogs (octreotide) | Documented | Somatostatin suppresses GH release, opposing MK-677 effect — separate by 4+ hours |
| Glucocorticoids | Theoretical | Both may impair glucose metabolism; additive hyperglycemia risk |
| GH therapy (somatropin) | Theoretical | Additive GH elevation — avoid combination to prevent supraphysiologic levels |
| GHRPs (GHRP-6, GHRP-2) | Theoretical | Additive GH secretion through overlapping pathways |
Use our interactive Drug Interaction Checker for real-time lookup.